Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
Yubrine Moraa Gachemba, Consultant Cardiologist at The Nairobi Hospital, shared EuroIntervention‘s post on LinkedIn:
“Pulmonary embolism care is entering a more nuanced era.
BETULA adds important randomized evidence that carefully selected patients with intermediate-high-risk PE may achieve earlier right ventricular unloading with low-dose, short-duration catheter-directed thrombolysis, without an observed increase in major bleeding.
But the larger question is not simply whether we can intervene earlier. It is which patients derive meaningful clinical benefit, at what risk, and within which health systems.
For Africa and the wider Global South, this matters enormously. Innovation in PE care must be accompanied by better risk stratification, multidisciplinary decision-making, appropriate imaging, and equitable access to reperfusion strategies.
The future of PE management will not be anticoagulation versus intervention. It will be precision in selecting the right patient, for the right therapy, at the right time.
Important data – and an evolving space to watch.”
EuroIntervention shared a post on LinkedIn about a recent article by Jacob Schultz et al., adding:
“In the randomised BETULA trial, low-dose, short-duration catheter-directed thrombolysis improved early right ventricular unloading compared with anticoagulation alone in patients with intermediate-high-risk pulmonary embolism, without increasing major bleeding.”
Title: Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial
Authors: Jacob Schultz, Gro Egholm, Mikael Kjær Poulsen, Bo Løfgren, Morten Würtz, Hanne Maare Søndergaard, Mads Jønsson Andersen, Jacob Valentin Hansen, Gratien Andersen, Shifan Thangavel, Søren Mellemkjær, Anushree Burade, Mannudeep Kalra, Jens Erik Nielsen-Kudsk, Asger Andersen
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety
-
Oct 18, 2026, 11:26Valentina Ajello: Does ANH Benefit Women in Cardiac Surgery?
-
Oct 18, 2026, 11:06Alex Ballout: Novel FUT1 Variant Linked to a Rare H-Deficient Blood Phenotype
-
Oct 18, 2026, 10:51Lethukwenama Letsoalo: Why Women’s Iron Status Matters Before Childbirth
-
Oct 18, 2026, 10:31Working Together for Better Outcomes in Hemophilia Care – Hemophilia Federation (India)
-
Oct 18, 2026, 08:02Neda Ashayeri: Global Perspectives on Hemophilia and Rare Bleeding Disorders in Abu Dhabi
-
Oct 18, 2026, 07:55Anu Thomas: A Stepwise Laboratory Approach to Positive IAT and Pretransfusion Compatibility
-
Oct 18, 2026, 07:49Matthew Hazell: Molecular Matching and the Future of Transfusion Practice
-
Oct 18, 2026, 07:05Behnood Bikdeli: Vasculearn Network Highlights Expert Perspectives on PE Risk Stratification and Advanced Therapies